The high incidence of breast cancer observed in young African-American women (7) and the apparent aggressiveness of the disease in this ethnic group (2) might be because of biologic differences, such as genetic susceptibility to environmental factors and/or hormonal levels. We have recently shown (3) that a polymorphism in the CYP1 Al gene, which is involved in estrogen metabolism, is significantly associated with breast cancer in African-American, but not in Caucasian, women. The endogenous metabolism of estrogens is primarily oxidative and involves hydroxylation of the steroid at either C2 (2-0HE1) or C16a (16a-0HEl). While the 2-OHE1 metabolites are essentially devoid of peripheral biologic activity, 16a-0HEl is an estrogen agonist (4,5). There is evidence of an inverse association between the 2-OHEl/16a-OHEl metabolite ratio and breast cancer risk (6). We present here the basal urinary estrogen metabolite ratio (as measured by an enzyme-linked immunosorbent assay method) in 33 healthy women aged 18-73 years (7). Women taking oral contraceptives or who were pregnant or lactating were excluded. African-American women had significantly lower 2-OHEl/16a-OHEl urinary metabolite ratios than did Caucasian women (Table 1) . No effect of age, weight, smoking status, or CYP1A1 genotype was observed.
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The observed differences in the estrogen metabolite ratio between Cau- casian and African-American women might be due to unknown genetic factors, diet, physical activity, or exogenous exposures, such as exposures to dioxins or pesticides (4, 5) . A larger study to address this question is planned. The confirmation of our results has important public health implications. The measurement of urinary estrogen metabolites might become a simple and useful marker for identifying groups of women for whom preventive health strategies are likely to be most beneficial; these prevention efforts could potentially involve dietary changes, increased physical activity, or chemopreventive interventions aimed at modulating the 2-OHEl/16a-OHEl metabolite ratio. 
